Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Alpha Tau Medical in a research report issued on Tuesday, August 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.15) for the quarter, down from their prior forecast of ($0.14). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.60) EPS.

Several other research firms have also weighed in on DRTS. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Barclays lifted their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Finally, Piper Sandler increased their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.80.

Alpha Tau Medical Stock Performance

Shares of DRTS stock opened at $13.87 on Thursday. The company has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $9.27. Alpha Tau Medical has a one year low of $3.00 and a one year high of $14.40. The stock has a market cap of $1.25 billion, a P/E ratio of -13.34 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.14 million.

Institutional Trading of Alpha Tau Medical

Several hedge funds have recently modified their holdings of DRTS. Mariner LLC increased its stake in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares in the last quarter. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical in the 4th quarter valued at about $48,000. Everhart Financial Group Inc. bought a new position in Alpha Tau Medical in the second quarter worth approximately $126,000. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Finally, Wells Fargo & Company MN raised its holdings in Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after buying an additional 17,500 shares during the last quarter. Institutional investors own 2.65% of the company’s stock.

Insider Transactions at Alpha Tau Medical

In other news, CFO Raphi Levy sold 32,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the sale, the chief financial officer directly owned 147,680 shares in the company, valued at approximately $1,599,374.40. The trade was a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 130,000 shares of company stock worth $1,519,143. 39.50% of the stock is owned by corporate insiders.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.